论文部分内容阅读
目的分析加替沙星注射液治疗肺癌并呼吸道感染的疗效及安全性。方法选取2012年12月—2014年2月我院收治的肺癌并呼吸道感染患者67例,将其随机分为对照组33例和试验组34例。试验组患者给予加替沙星注射液治疗,对照组患者给予诺氟沙星治疗,均连续用药1周,观察两组患者治疗后临床疗效、细菌清除情况及治疗期间不良反应情况。结果试验组患者总有效率为91.2%、细菌清除率为94.1%,高于对照组的66.7%、69.7%(P<0.05);对照组患者不良反应发生率为15.2%,与试验组的14.7%比较,差异无统计学意义(P>0.05)。结论加替沙星注射液治疗肺癌并呼吸道感染可有效提高临床疗效、细菌清除率,且不良反应较少。
Objective To analyze the efficacy and safety of gatifloxacin injection in the treatment of lung cancer and respiratory tract infections. Methods Sixty-seven patients with lung cancer and respiratory tract infection admitted to our hospital from December 2012 to February 2014 were randomly divided into control group (n = 33) and experimental group (n = 34). Patients in the test group were treated with gatifloxacin injection, while those in the control group were treated with norfloxacin for 1 week. The clinical efficacy, bacterial clearance and adverse reactions during the treatment were observed in both groups. Results The total effective rate of the experimental group was 91.2%, the bacterial clearance rate was 94.1%, which was higher than 66.7% and 69.7% of the control group (P <0.05). The incidence of adverse reactions in the control group was 15.2% %, The difference was not statistically significant (P> 0.05). Conclusion Gatifloxacin injection in the treatment of lung cancer and respiratory tract infection can effectively improve the clinical efficacy, bacterial clearance, and fewer adverse reactions.